IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor blockade.
We hypothesize that corticotropin-releasing hormone (CRH), a regulator of the hypothalamic-pituitary-adrenal (HPA) axis, is involved in sleep-wake regulation on the basis of observations that the CRH receptor antagonist astressin, after a delay of several hours, reduces waking and increases slow-wave sleep (SWS) in rats. This delay suggests a cascade of events that begins with the HPA axis and culminates with actions on sleep regulatory systems in the central nervous system. One candidate mediator in the brain for these actions is interleukin (IL)-1. IL-1 promotes sleep, and glucocorticoids inhibit IL-1 synthesis. In this study, central administration of 12.5 microgram astressin into rats before dark onset reduced corticosterone 4 h after injection and increased mRNA expression for IL-1alpha and IL-1beta but not for IL-6 or tumor necrosis factor-alpha in the brain 6 h after injection. To determine directly whether IL-1 is involved in astressin-induced alterations in sleep-wake behavior, we then pretreated rats with 20 microgram anti-IL-1beta antibodies before injecting astressin. The increase in SWS and the reduction in waking that occur after astressin are abolished when animals are pretreated with anti-IL-1beta. These data indicate that IL-1 is a mediator of astressin-induced alterations in sleep-wake behavior.
Chang
F C
FC
Neuroscience Graduate Program, University of Texas Medical Branch, Galveston, Texas 77550-0431, USA.
Opp
M R
MR
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001831:Body Temperature; D003345:Corticosterone / Q000097:blood; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D007030:Hypothalamo-Hypophyseal System / Q000502:physiology; D007074:Immunoglobulin G / Q000494:pharmacology; D007375:Interleukin-1 / Q000235:genetics* / Q000276:immunology / Q000378:metabolism*; D015850:Interleukin-6 / Q000235:genetics; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D010913:Pituitary-Adrenal System / Q000502:physiology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors* / Q000502:physiology*; D012890:Sleep / Q000187:drug effects / Q000502:physiology*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014851:Wakefulness / Q000187:drug effects / Q000502:physiology
D007074:Immunoglobulin G; D007375:Interleukin-1; D015850:Interleukin-6; D018696:Neuroprotective Agents; D010446:Peptide Fragments; D012333:RNA, Messenger; D018019:Receptors, Corticotropin-Releasing Hormone; D014409:Tumor Necrosis Factor-alpha; C104416:astressin; D003346:Corticotropin-Releasing Hormone; D003345:Corticosterone